Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
NCT Number:
NCT06058377
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Breast
Study Objectives:
To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab.
Study Documents
(MUSC NetID required for document access)